PROTAC Solutions at Creative Biolabs Fully Support Novel Drug Development

Having been immersed in novel drug development for decades, Creative Biolabs is committed to expediting the development of drug discovery. The company has established a one-stop PROTAC service platform and updated its PROTAC solutions, providing a range of discovery and development services to comprehensively support scientists’ drug development.

New York, USA – November 10, 2022 – Since great advancements have been made in novel drug discovery through the continuous design and optimization of PROTAC, a number of assays that verify the efficacy of PROTAC in the drug development stage, ranging from administration to intracellular target degradation, have been proposed. In order to meet the vast number of assay demands, Creative Biolabs, a biotechnology CRO company specializing in providing drug discovery solutions and services, has teamed a group of scientific minds and technicians with experience in drug discovery for years and invented an advanced PROTAC development platform to help clients solve their difficulties in drug development.

“We’ve put a lot of effort into providing comprehensive solutions regarding PROTAC assays,” according to a scientist at Creative Biolabs, “and we can provide binary target engagement assays to monitor the affinity and specificity of PROTAC with target proteins, helping researchers accelerate the drug development progress.”

In addition, due to the restricted permeability of PROTAC toward the cell membrane, it is essential to monitor the cell permeability of PROTAC, ensuring sufficient cellular absorption. Creative Biolabs can provide customers with comprehensive tests for the cell permeability of PROTAC, which are listed below:

* Parallel artificial membrane permeability assay

* Caco-2 permeability assay

* Madin-Darby canine kidney (MDCK) permeability assay

Besides in vitro assays, Creative Biolabs has also made great efforts in the invention of novel ligands to induce receptor-interacting protein kinase 2 (RIPK2) protein degradation utilizing the PROTAC technology.

“RIPK2 has great impacts on the innate immune response and the development of inflammatory cytokines, so it is important to design a suitable ligand for RIPK2 PROTAC,” added the scientist.

Furthermore, Creative Biolabs uses virtual library screening (VLS) to filter potent ligands for research applications, such as small molecular inhibitors targeting RIPK2, assessing the effect of these inhibitors toward RIPK2 through in vitro and in vivo experiments, thus discovering ligands with the most suitable binding affinity.

To learn more about comprehensive PROTAC solutions at Creative Biolabs, please visit

About Creative Biolabs

Creative Biolabs, as an industry-leading PROTAC solution provider, has been working diligently in the field of innovative medications for a few decades and continues to stay current with trends. The company is confident in providing the most suitable PROTAC solutions according to the specific project demands of customers. Shortly, Creative Biolabs will present its novel strategies for drug discovery research at the international conference in December 2022.

Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States